Until recently, early in vivo efficacy evaluation for anti-PD-1, anti-PD-L1 and combinations, implied the use of expensive humanized mouse models and lasts months. Current oncology drug development strategies are based on a combination approach. The key question is: « what is the best combination », in optimal costs and time.
Identifying the best combinations and eliminating the low-value ones as early as possible is a key milestone in the preclinical phase.
To address these critical points, Inovotion’s R&D team has developed a standardized and accurate in vivo efficacy prescreening assay, based on the chicken embryo model.
Using this very effective approach, researchers can quickly and easily access early in vivo prescreening to select their most effective immune-modulation combination, at an affordable cost.
